Browse the corpus

Cat scratch disease is a zoonotic infection caused by Bartonella henselae, transmitted through scratches, bites, or flea exposure from cats. The condition most often presents as regional lymphadenopathy following a cutaneous inoculation lesion, with fever and malaise frequently accompanying nodal swelling. Atypical manifestations—including neuroretinitis, encephalopathy, hepatosplenic lesions, or osteomyelitis—occur less commonly but require prompt recognition, particularly in immunocompromised patients. Diagnosis depends on a thorough history, careful physical examination, and supportive serologic testing, along with consideration of conditions that mimic cat scratch disease, such as Kawasaki disease and select viral or fungal infections. Appropriate antimicrobial therapy and supportive care generally lead to full recovery, and early identification helps prevent unnecessary procedures and delays in treatment. The learning activity provides clinicians with a concise yet comprehensive review of the epidemiology, clinical features, diagnostic approach, and evidence-based management of cat scratch disease. Instruction emphasizes accurate history taking, targeted testing, and recognition of atypical presentations to improve diagnostic precision. The course also addresses potential complications and outlines management considerations for vulnerable populations. Collaboration within an interprofessional team—such as infectious disease specialists, ophthalmologists, neurologists, surgeons, nurses, and primary care clinicians—enhances communication, streamlines evaluation, and supports informed decision-making. Engagement in this program strengthens clinical reasoning, promotes timely, effective treatment, and contributes to improved patient outcomes across care settings. Objectives: Differentiate cat scratch disease from other causes of lymphadenopathy, such as Kawasaki disease and other infections. Apply current evidence-based diagnostic modalities, including serologic and molecular testing, to improve early detection and reduce misdiagnosis of cat scratch disease. Implement appropriate management strategies tailored to disease severity and patient immune status to optimize clinical outcomes. Collaborate effectively within an interprofessional healthcare team to enhance patient education, prevention, and comprehensive care for individuals affected by cat scratch disease.

Apply current evidence-based diagnostic modalities, including serologic and molecular testing, to improve early detection and reduce misdiagnosis of cat scratch disease. Implement appropriate management strategies tailored to disease severity and patient immune status to optimize clinical outcomes. Collaborate effectively within an interprofessional healthcare team to enhance patient education, prevention, and comprehensive care for individuals affected by cat scratch disease. Access free multiple choice questions on this topic.

Cat scratch disease (CSD), also known as cat scratch fever, is a febrile illness primarily characterized by subacute regional lymphadenopathy caused by the intracellular, gram-negative bacillus Bartonella henselae. The infection often resolves spontaneously within 2 to 4 weeks in immunocompetent individuals, but more severe or disseminated forms can occur in both immunocompetent and immunocompromised hosts. CSD was first identified in the 1930s, with its link to cats recognized in the 1950s. Transmission mainly occurs through scratches or bites from infected cats, especially kittens, which carry B henselae in their claws and oral cavity, often transmitted among cats via fleas. The hallmark clinical presentation includes a papule or pustule at the inoculation site, followed by tender regional lymphadenopathy proximal to it, frequently accompanied by low-grade fever. Considering CSD in the differential diagnosis of any acute, subacute, or chronic lymphadenopathy is important. The innate immune response, including activation of neutrophils and macrophages, plays a key role in local containment of the infection, typically resulting in granulomatous and suppurative lymphadenitis. Prevention focuses on flea control in cats and minimizing injuries caused by cats. Treatment depends on the severity of the illness and the patient's immune status, with antibiotic therapy reserved for complicated cases.[1][2][3][4]

The most common cause of CSD is B henselae. This fastidious, intracellular, gram-negative rod primarily infects lymph nodes near the site of inoculation, usually following a scratch or bite from a kitten. Descriptions of CSD date back over 50 years, but it took decades to pinpoint B henselae as the responsible pathogen. Early research faced challenges due to cross-reactivity between Chlamydia and Bartonella species; however, techniques such as electron microscopy and the Warthin-Starry silver stain enabled scientists to visualize the bacteria as black spots within affected lymph nodes. During the AIDS epidemic, bacillary angiomatosis, marked by Warthin-Starry-positive bacteria, was recognized to involve the same organism, further confirming B henselae's role in human disease. Transmission occurs from cats to humans through scratches, bites, or contact with flea-contaminated claws or saliva, with fleas essential for maintaining the bacteria among cats. This historical and microbiological background forms the foundation of our current understanding of how CSD develops and spreads.[5][6][7][https://www.cdc.gov/bartonella/about/about-bartonella-henselae.html] B clarridgeiae has also been recognized as a zoonotic pathogen that can cause CSD, presenting with clinical features similar to those of Bartonella henselae infection. Serologic and molecular studies have confirmed its etiologic role, although it is identified much less frequently than B henselae.[8]

CSD typically causes mild illness in immunocompetent hosts, with 55% of cases in children younger than 18, of whom 60% are boys. In the United States, more than half of cases occur from September through January, and the disease is found worldwide. Cats, especially those younger than 1, act as vectors by acquiring B henselae from bites of the cat flea (Ctenocephalides felis), leading to bacteremia; cats often remain asymptomatic carriers. Human transmission occurs through scratches, bites, or contact with infected cat saliva via broken skin. B henselae is difficult to culture but can be detected through serologic or polymerase chain reaction testing. Regions with warmer climates and higher flea populations report higher incidence rates, with cases peaking seasonally from late summer to winter. Children aged 5 to 9 have the highest incidence, likely due to greater exposure to kittens. Recent studies' results report an overall CSD incidence of approximately 4.5 to 9.4 cases per 100,000 people annually, with most hospitalizations occurring in younger children and adult women. During the COVID-19 pandemic, some areas saw increased incidence, possibly related to more pet contact during quarantine. Preventive measures include flea control and reducing cat-inflicted injuries, especially in households with children.[9]

CSD typically presents with lymphadenopathy proximal to the site of inoculation, which develops over 1 to 2 weeks. In immunocompetent individuals, the host mounts a granulomatous inflammatory reaction characterized by granuloma formation with central necrosis and the recruitment of histiocytes, lymphocytes, and multinucleated giant cells. The affected lymph nodes become enlarged and tender, and this condition may last for weeks to months, sometimes leading to suppuration. In immunocompromised individuals, a vascular-proliferative response can occur, marked by aggressive angiogenesis and neovascularization, similar to bacillary angiomatosis. CSD lymphadenopathy can be solitary or multiple, commonly in the axillary, epitrochlear, cervical, supraclavicular, or submandibular regions. Beyond the lymph nodes, dissemination to the eye, liver, spleen, and central nervous system can occur, especially in immunosuppressed individuals. Radiologic findings often correlate with histologic stages, with early, intermediate, and late disease stages showing distinctive patterns of lymph node enhancement and central necrosis. The disease process reflects the interaction between bacterial persistence inside macrophages and the host immune response, which mediates both local containment and systemic symptoms.

Histologically, CSD is characterized by granulomatous inflammation in affected lymph nodes, usually with centrally located microabscesses. These granulomas consist of a necrotic core surrounded by palisading histiocytes and an outer rim of lymphocytes and fibroblasts. Similar histopathological changes can also be observed at the inoculation site. Histology progresses through stages: early disease shows lymphoid hyperplasia and neutrophilic aggregation; intermediate stages display irregular granulomas with stellate abscesses marked by central necrosis; and late stages show replacement of inflammation and necrosis with spindle-shaped fibroblastic proliferation. These features can help distinguish cat scratch disease from other causes of lymphadenopathy, such as lymphoma or mycobacterial infections. Radiologic imaging of affected lymph nodes often aligns with these histopathologic stages, showing characteristic patterns of enhancement and necrosis. The presence of B henselae can be confirmed by polymerase chain reaction or immunohistochemical staining of biopsy specimens, although viable bacteria are often scarce due to the host immune response.

Eighty-five to ninety percent of immunocompetent children with CSD disease develop self-limited lymphadenopathy, and fewer than half experience a fever.[10] Disseminated illness, although rare, tends to occur in very young children, older adults, or immunocompromised individuals, such as transplant recipients or individuals with HIV infection. The disease can involve multiple systems, including the skin, lymphatic system, and internal organs, with less common involvement of the ocular and nervous systems. Cutaneous manifestations typically begin as an erythematous papule, vesicle, or nodule, known as the primary inoculation lesion, which lasts 1 to 3 weeks but may persist for several months. Primary inoculation may occur on mucous membranes, such as the conjunctiva, and heal without scarring, making it easy to miss. Careful examination of intertriginous areas, skin creases, and the scalp is essential to detect these lesions. Lymphatic involvement typically presents as tender, regional lymphadenopathy that may be solitary or involve multiple nodes measuring 1 to 5 cm in diameter, often with overlying erythema. About 10% of affected nodes may suppurate. Commonly involved lymph nodes include the axillary, epitrochlear, cervical, supraclavicular, and submandibular groups. Lymphadenopathy generally persists for 1 to 4 months. Visceral involvement can affect the liver and spleen, presenting with fever, weight loss, and abdominal pain, along with elevated acute phase reactants and abnormal liver function tests. CSD disease may account for up to one-third of children presenting with a fever of unknown origin. Ophthalmic complications occur in fewer than 10% of pediatric cases and include neuroretinitis, papillitis, optic neuritis, and, most notably, Parinaud oculoglandular syndrome. This syndrome features conjunctival inoculation, local preauricular or cervical adenopathy, and severe conjunctival inflammation that resolves in weeks, although lymphadenopathy may persist for months. Other ocular manifestations include focal or multifocal chorioretinitis, panuveitis, and neuroretinitis.

Ophthalmic complications occur in fewer than 10% of pediatric cases and include neuroretinitis, papillitis, optic neuritis, and, most notably, Parinaud oculoglandular syndrome. This syndrome features conjunctival inoculation, local preauricular or cervical adenopathy, and severe conjunctival inflammation that resolves in weeks, although lymphadenopathy may persist for months. Other ocular manifestations include focal or multifocal chorioretinitis, panuveitis, and neuroretinitis. Chorioretinitis presents with focal white lesions in the posterior segment of the eye, which may be associated with branch retinal artery occlusion and progress to retinal detachment. Neuroretinitis is characterized by optic disc edema and a macular star pattern of retinal exudates. Patients typically present with acute, painless visual loss.[11][12] Neurologic complications include ataxia, cranial nerve palsies, dementia-like syndromes in older adults, and, in children, presentations of encephalitis or aseptic meningitis. Status epilepticus has rarely been reported. Musculoskeletal symptoms such as arthralgias, myalgias, and frank arthritis are also associated with CSD.

A presumptive diagnosis of CSD can generally be made based on a compatible history of cat exposure and characteristic clinical features. The causative organism, B henselae, is difficult to culture, so diagnosis typically relies on serologic testing, including enzyme immunoassay or indirect immunofluorescence assay. However, negative serologic results do not exclude disease, especially if blood tests are performed before an adequate host antibody response develops. Lymph node biopsy is not routinely required but may be considered if the diagnosis is unclear. Historically, excision of affected lymph nodes has been avoided due to the risk of fistula formation, with ultrasound-guided needle aspiration preferred for obtaining tissue. Recent advances, such as metagenomic next-generation sequencing, enable rapid, unbiased detection of B henselae DNA in tissue and other specimens, thereby increasing diagnostic accuracy and helping differentiate CSD from other granulomatous infections, such as tuberculosis. Overall, diagnosis and treatment decisions should integrate clinical features, exposure history, and multiple diagnostic methods, with clinical suspicion guiding treatment even if early serologies are negative.[13][14][15] Early titers can be negative despite active infection; hence, treatment should be initiated based on clinical grounds to avoid delays. Repeat serology or molecular testing may demonstrate seroconversion and confirm the clinical diagnosis. This approach balances the limitations of diagnostic tests with the need for timely management to prevent complications.

In mild cases of CSD, treatment may not be necessary as the illness is often self-limited. Supportive care, including antipyretics, anti-inflammatory medications, and warm compresses to the inoculation site, is typically sufficient. In immunocompetent individuals with mild to moderate disease, a 5-day course of azithromycin can help relieve pain from severe lymphadenopathy. However, it has not been proven to shorten the overall duration of symptoms. The azithromycin dose is 10 mg/kg on day 1 and 5 mg/kg on days 2 through 5, with a maximum adult dose of 500 mg on day 1 and 250 mg on days 2 through 5. Immunocompromised individuals need antibiotic treatment to prevent progression to severe systemic disease. For disseminated or severe infections, other antibiotics such as rifampin, trimethoprim-sulfamethoxazole, or ciprofloxacin may be used. Most children recover on their own within 2 to 4 months, but complicated cases, especially in immunosuppressed individuals, might require prolonged antibiotic courses and supportive care.[9][16][17]

The differential diagnosis encompasses a wide range of causes of acute, subacute, and chronic lymphadenopathy. Viral infections such as cytomegalovirus, HIV, and Epstein-Barr virus lead to diffuse lymphadenopathy and should be considered. Skin papules resembling the inoculation lesion in CSD may also appear in fungal infections, leishmaniasis, and nocardiosis. In immunocompromised hosts, a broader spectrum of infectious agents may be encountered. Notably, HIV-associated bacillary angiomatosis can mimic Kaposi sarcoma, complicating diagnosis. Radiologic findings such as the 'rose flower' sign on computed tomography or MRI and a history of cat exposure help differentiate CSD from other causes, including neoplasms, tuberculosis, and soft tissue tumors.[18] Moreover, histologic examination is crucial, as CSD can coexist with malignant or mycobacterial diseases; thus, lymph node biopsy and molecular testing are essential when the diagnosis is uncertain or the presentation is atypical. A comprehensive history and physical exam, coupled with appropriate lab and imaging studies, aid in distinguishing it from other etiologies, ensuring accurate diagnosis and treatment. Kawasaki disease (KD) is an important differential diagnosis because it shares features with CSD, such as fever, rash, conjunctivitis, and cervical lymphadenopathy. Differentiating KD from atypical or systemic CSD can be difficult, especially in children, with some cases showing co-occurrence or mimicking features.[18]

In 90% to 95% of cases, CSD resolves spontaneously in children with supportive care, typically analgesics, antipyretics, and warm compresses. Uncomplicated illness generally lasts 2 to 4 months, with gradual resolution of lymphadenopathy. Antibiotic therapy, most commonly azithromycin, may accelerate lymph node regression but does not substantially shorten the overall course of symptoms. Disseminated or atypical disease, particularly in immunocompromised individuals, can result in prolonged symptoms lasting several months to over a year and may lead to organ-specific complications. Central or peripheral nervous system involvement may cause persistent neurologic deficits despite appropriate treatment. Mortality is rare among immunocompetent individuals, and most patients acquire lifelong immunity following infection. Prognosis is more guarded in immunosuppressed hosts due to the risk of severe systemic disease.[https://www.healthychildren.org/English/health-issues/conditions/from-insects-animals/Pages/Cat-Scratch-Disease.aspx ]

Complications of CSD vary depending on the host and extent of dissemination. In immunocompetent children, CSD is usually self-limited, but potential complications include suppurative lymphadenitis with abscess formation, which occurs in about 10% of cases. Disseminated infection can involve visceral organs, including the liver and spleen, leading to hepatosplenic lesions, prolonged fever, and weight loss. Ocular complications, seen in 2% to 8% of cases, include Parinaud oculoglandular syndrome, neuroretinitis, optic neuritis, and, less commonly, focal or multifocal chorioretinitis that can cause retinal detachment. Neurological complications such as aseptic meningitis, encephalitis, cranial neuropathies, and rarely status epilepticus may occur, especially in immunocompromised patients. Musculoskeletal complaints, including arthralgias, myalgias, and arthritis, have also been reported. Immunocompromised hosts are at higher risk for severe manifestations, including bacillary angiomatosis and peliosis hepatis (a rare vascular condition characterized by blood-filled cystic spaces within the liver parenchyma), which cause proliferative vascular lesions of skin and internal organs. Though rare, fatal outcomes may occur in this group. Most complications resolve with appropriate antimicrobial therapy and supportive care, but neurological sequelae can persist. Awareness of these complications is critical for timely diagnosis and management.

In some cases of CSD, consultation may be indicated depending on the severity and complexity of the presentation: Infectious disease specialist: For atypical, severe, or disseminated cases, immunocompromised patients, or when the diagnosis and management are unclear Ophthalmologist: When there is ocular involvement, such as Parinaud oculoglandular syndrome, neuroretinitis, or other eye complications Neurologist: In cases with neurological manifestations such as encephalitis, aseptic meningitis, or cranial nerve palsies Surgeon or interventional radiologist: For management of suppurative lymphadenitis requiring drainage or biopsy Hematologist/oncologist: If lymphadenopathy raises suspicion for malignancy or when differentiating from lymphoma Primary care clinician or pediatrician: For typical uncomplicated cases that benefit from ongoing monitoring and symptomatic management

Deterrence and patient education for CSD focus on reducing the risk of transmission from cats to humans. Key prevention measures include avoiding rough play with cats, which can lead to scratches or bites, especially with kittens, who are more likely to carry B henselae. Promptly and thoroughly washing any cat scratches or bites with soap and water is essential to reduce the risk of infection. Keeping cats indoors reduces their exposure to fleas (Ctenocephalides felis), the vector for B henselae, and effective flea control measures, such as veterinary-recommended flea prevention products, should be used. Avoiding contact with stray or feral cats, discouraging cats from licking open wounds, and keeping cat claws trimmed are also essential strategies. Owners and high-risk individuals, including children and immunocompromised persons, should be particularly vigilant. Educating patients about the typical presentation, the importance of hygiene after cat interaction, and when to seek medical care is crucial to minimizing complications. Currently, no human vaccine is available, so prevention relies heavily on behavioral and environmental control efforts.

CSD is a common cause of lymphadenopathy, especially in children. Diagnosis relies on a thorough history and physical examination, and a high index of suspicion based on cat contact and characteristic clinical features. The disease course can range from benign and self-limited to severe and protracted, with age and comorbid conditions influencing management decisions. Proper flea control in cats and supervision of children around young cats are essential preventive measures. Early recognition reduces unnecessary invasive procedures, and serological or molecular confirmatory testing can support the diagnosis when needed. CSD should always be considered in the differential diagnosis of acute or chronic lymphadenopathy in pediatric individuals. [https://publications.aap.org/redbook/book/755/chapter-abstract/14075629/Bartonella-henselae-Cat-Scratch-Disease?redirectedFrom=fulltext]

CSD is relatively common in North America, and many patients initially present to emergency departments. Due to its varied clinical presentation and potential for multisystem involvement, optimal diagnosis and management are best achieved by an interprofessional healthcare team that includes primary care clinicians, infectious disease specialists, neurologists, surgeons, ophthalmologists, and internists. Nurses play a key role in early triage, patient education, monitoring for clinical deterioration, and reinforcing wound care and symptom-management strategies. Pharmacists assist in selecting appropriate antimicrobial therapy, screening for drug interactions, optimizing dosing in special populations, and counseling patients on medication adherence and adverse effects. Public health professionals and laboratory personnel contribute to accurate reporting, diagnostic support, and outbreak surveillance. Immunocompetent persons generally experience excellent outcomes, although neurological involvement can lead to persistent deficits despite appropriate treatment. Mortality in immunocompetent individuals is rare. Lymphadenitis may persist for several months, yet most patients develop lifelong immunity following infection. In contrast, those who are immunocompromised face a guarded prognosis, as they are at increased risk for severe systemic disease and complications. Coordinated care, effective communication among team members, and early recognition of neurological and systemic involvement are crucial to improving healthcare outcomes in CSD.[19][20]